NEW YORK (TheStreet) --Pfizer (PFE) reported weaker-than-expected 2016 third-quarter earnings results before the market open on Tuesday. The largest U.S. drugmaker posted earnings of 61 cents per share, below analysts' estimated 62 cents per share. Revenue came in at $13 billion, largely in-line with Wall Street's projections.

Pfizer lowered its full-year earnings guidance to between $2.38 and $2.43 per share, down from $2.38 to $2.48 per share. The discontinuation of the drug Bococizumab would cut 4 cents a share from its earnings on both GAAP and an adjusted basis.

Barbara Ryan Advisors founder Barbara Ryan discussed some of the reasons Pfizer lowered its full-year earnings guidance, during Tuesday morning's "Squawk Box" on CNBC.

"I think there're a couple of things. If you have noticed, very recently, the biotech sector has come under an enormous amount of pressure; the whole healthcare industry has not done terribly well this year. Some rotation, some election concern, they've become more pronounced more recently," she explained.

Then came issues and discrepancies over drug pricing brought about with the Mylan (MYL) EpiPen controversy.

"I think the other piece is there was a strategic component to Pfizer, the sum of the parts analysis, which was that they were going to break into separate business units and they have made the decision to not do that," Ryan said.

The poor performance in the stock, as well in Pfizer's specialty pharma sector can be potentially linked to the decision to remain one company, she noted.

Shares of Pfizer opened lower on Tuesday.

(Pfizer is held in the Dividend Stock Advisor portfolio. See all of the holdings with a free trial.)

Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.

Pfizer's strengths such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins outweigh the fact that the company has had sub par growth in net income.

You can view the full analysis from the report here: PFE

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign